Liquidia Corporation COO and CFO to Speak at BofA Securities Health Care Conference 2024 on Pulmonary Hypertension Treatment and Future Developments

Liquidia Corporation, a biopharmaceutical company that specializes in products for pulmonary hypertension and other uses of its PRINT® Technology, has announced that Michael Kaseta, COO and CFO, will be speaking at the BofA Securities Health Care Conference 2024 in Las Vegas, Nevada on May 14, 2024. The fireside chat will begin at 5:00 p.m. PT and a webcast will be available on Liquidia’s website for investors and interested parties.

Liquidia Corporation operates through its subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. They are also working on L606, a liposomal formulation of treprostinil for use in North America. Liquidia PAH focuses on commercializing pharmaceutical products for pulmonary diseases.

An archived version of the presentation will be available on Liquidia’s website for at least 30 days following the event. For more information about Liquidia Corporation, you can visit their website at www.liquidia.com. For investor inquiries, you can contact Jason Adair, the Chief Business Officer, at 919.328.4350 or jason